ArticleJournal of fish diseases2026
Vaccination Reduces Shedding of Salmonid Alphavirus Subtype 3, but Bacterial Co-Infection Influences the Effect.
Article in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction and Immunological Evaluation of a Bivalent DNA Vaccine TargetingAnimals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Waterborne horizontal transmission of viral diseases in fish relies on the release of infectious virus particles (termed shedding) into the aquatic environment. Both the rate and duration of shedding are critical for efficient viral spread, making interventions that reduce shedding valuable for disease control. While vaccines primarily aim to protect individuals from infection and severe disease, they should ideally also limit pathogen transmission by reducing shedding. In this study, we evaluated the capacity of two commercial vaccines-Clynav (DNA vaccine) and AlphaJect Micro 1-PD (inactivated whole-virus vaccine) to reduce Salmonid alphavirus subtype 3 (SAV3) shedding following experimental infection of Atlantic salmon post-smolts. In individually housed fish, AlphaJect Micro 1-PD significantly reduced the proportion of SAV3-shedding fish, duration of shedding, and cumulative shedding, while Clynav significantly reduced shedding duration and the proportion of shedding fish. In cohort tanks (each containing 60 fish), all of which had concurrent inadvertent Tenacibaculum dicentrarchi co-infection, AlphaJect Micro 1-PD significantly reduced the cumulative shedding but increased the duration of shedding. In comparison, Clynav vaccination reduced both cumulative shedding and shedding duration, though not significantly. These results demonstrate the potential of vaccines to limit SAV3 transmission, while also highlighting how co-infections likely influence vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.